yapteadin1 tfa

YAP-TEAD-IN-1 TFA, a competitive inhibitor of the YAP–TEAD interaction (IC50: 25 nM), exhibits higher binding affinity to TEAD1 (Kd: 15 nM) compared to YAP (50-171) (Kd: 40 nM).

Jagged-1 (188-204) TFA(219127-21-6 free base) is a fragment of the JAG-1 protein. JAG-1 is Notch ligand, a peptide that is the most conspicuously expressed ligand in skin. JAG-1 induces epidermal maturation. Exposing submerged keratinocytes monolayers to JAG-1 with elevated calcium concentration produces stratification with loricrin expression and NF-alphaB activation.

Rotigaptide TFA(355151-12-1 free base) is a novel and specific modulator of Cx43 and is a potent AAP. Rotigaptide TFA(355151-12-1 free base) prevents the uncoupling of Cx43-mediated gap junction communication and normalizes cell-to-cell communication during acute metabolic stress.

JAG-1, scrambled TFA is a scrambled sequence of JAG-1(188-204).

Angiotensin 1/2 (1-9)TFA is containing the amino acids 1-9 that are converted from Angiotensin I/II peptide.

Nociceptin (1-13), amide is a potent agonist Opioid receptor-like1 (ORL1) receptor with a pEC50 of 7.9 for mouse vas deferens and a Ki of 0.75 nM for binding to rat forebrain membranes.

pro-asp TFA(85227-98-1 free base) (TLβ4) down-regulate skin inflammation in mouse skin.

Biotin-β-Amyloid (1-42), human TFA, also known as Biotin-Amyloid β-Peptide (1-42) (human) TFA, is a biotin-labeled 42-amino acid peptide implicated in the pathogenesis of Alzheimer's disease.

740 Y-P(TFA)(1236188-16-1 free base) (740YPDGFR(TFA)) is a potent and cell-permeable activator of PI3K.

GLP-1(32-36)amide TFA, a pentapeptide derived from the C-terminal end of the glucoregulatory hormone GLP-1, has demonstrated the ability to mitigate weight gain and regulate glucose metabolism in diabetic mice [1] [2].

FSL-1 TFA, a toll-like receptor 2/6 (TLR2/6) agonist derived from bacteria, bolsters resistance against experimental HSV-2 infection[1] and stimulates MMP-9 production via the TLR2 and NF-κB/AP-1 signaling pathways in monocytic THP-1 cells[2].

Orexin B, human (TFA) is an endogenous agonist at Orexin receptor with Kis of 420 and 36 nM for OX1 and OX2.

HPV16 E7 (86-93) TFA is a human leukocyte antigen (HLA)-A2.1 restricted HPV16 E7-derived peptide.

This is a hypoxia-inducible factor-1 (HIF-1 a) 19-mer fragment. HIF-1 functions as master regulator of response to oxygen homeostasis. Hypoxia-induced gene expression is initiated when HIF-1 subunit is stabilized in response to a lack of oxygen. This part

Dynorphin B (1-13), a 13 amino acid, is an extraordinarily potent opioid peptide.

TAT-DEF-Elk-1 TFA is a cell-penetrating peptide Elk-1 inhibitor, mimics and specifically interferes with the DEF domain of Elk-1. TAT-DEF-Elk-1 blocks Elk-1 phosphorylation and prevents Elk-1 nuclear translocation without interfering with ERK nor MSK1 act

TAT TFA (YGRKKRRQRRR) is derived from human immunodeficiency virus (hiv-1) transcription reverse activator TAT, is a cell penetrating peptide.

Calcitonin Gene Related Peptide (CGRP) II, rat (TFA) is a neuropeptide with 37 amino acid.

Super-tdu (1-31) TFA is an endogenous ligand of heptapeptide receptor and has a strong anti-analgesic effect.

ACTH (1-14) (TFA) is a polypeptide of corticotrophin, which promotes the release of cortisol.

Glucagon-like peptide 1 (1-37), human (TFA), is a highly potent agonist of the GLP-1 receptor and is a pancreatic hormone synthesized through post-translational processing of proglucagon.

LyP-1 TFA, a cyclic nine-amino-acid peptide, exhibits selective binding to p32 receptors, which are overexpressed in a variety of tumor-associated cells [1].

Grb2 SH2 Domain Inhibitor 1 TFA is a cyclic cell-penetrating peptide (CPP) featuring a conformationally restricted d-pro-l-pro motif ring (AF Φ Rpprrfq), where Φ represents L-naphthylalanine, R signifies D-arginine, and P stands for D-proline. It primarily functions as a cyclic peptide inhibitor.

Pam3CSK4 TFA (Pam3Cys-Ser-(Lys)4 TFA) is a Toll-like receptor 1 2 agonist with EC50 of 0.47 ng mL for human TLR1 2.

A8SGLP-1 TFA, an orally active GLP-1 analogue, features a serine substitution for alanine at position 8. This compound effectively lowers blood glucose in db/db mice, maintaining its function [1].

NEP(1-40) TFA is a peptide antagonist of the Nogo-66 receptor (NgR), which attenuates myelin-derived inhibition and mitigates injury-induced shifts in microglial morphology distributions [1].

Gastric inhibitory peptide 1 (GIP-1) (3-42), a fragment of the incretin hormone GIP and antagonist to the GIP receptor, is generated through the action of serum dipeptidyl peptidase 4 (DDP-4). When administered at 25 nmol/kg to an ob/ob mouse diabetes model, GIP-1 (3-42) elevates plasma glucose levels and lowers plasma insulin levels, demonstrating its effect on reducing insulin secretion from BRIN-BD11 pancreatic cells at a concentration of 100 nM.

Interphotoreceptor retinoid-binding protein (1-20) (IRBP1-20), a dodecapeptide fragment of retinoid-binding protein 3, plays a crucial role in pigment regeneration by facilitating the transport of retinol and retinal between photoreceptor cells and the retinal pigment epithelium. It has been utilized to provoke autoimmune uveoretinitis in C57BL/6 mice, possessing the H-2b haplotype. Furthermore, IRBP1-20 at a concentration of 3 µM enhances the secretion of IL-4, IL-5, and IL-6 from primary mouse spleen lymphocytes. Immunization and subsequent rechallenge with IRBP1-20 lead to increased ear swelling, inflammation of ocular blood vessels, infiltration by immune cells, damage to the photoreceptor layer, and retinal detachment in IFN-γ-deficient mice.

MART-1 (26-35) (human) TFA is an amino acid residue of 26-35 protein.

Dynorphin A (1-10) (TFA), an endogenous opioid neuropeptide, interacts with the extracellular loop 2 of the κ-opioid receptor and inhibits NMDA-activated currents with an IC50 of 42.0 μM.

PAR 4 (1-6) TFA (GYPGQV TFA), a hexapeptide derived from protease-activated receptor 4 (PAR 4), serves as a specific agonist for PAR 4, exhibiting targeted activation properties.

ACTH (1-17) TFA, an analogue of adrenocorticotropin, is a potent agonist for the human melanocortin 1 (MC1) receptor with a dissociation constant (K i) of 0.21 nM.

K-(D-1-Nal)-FwLL-NH2 TFA is a potent, high-affinity inverse agonist of the ghrelin receptor with Ki values of 4.9 nM in COS7 cells and 31 nM in HEK293T cells, effectively inhibiting ghrelin receptor-mediated Gq- and G13-dependent signaling pathways.

Parathyroid Hormone (1-34), bovine TFA, a potent agonist of the parathyroid hormone (PTH) receptor, elevates calcium and inorganic phosphate levels in vivo and is used in osteoporosis research [1].

Substance P(1-7) TFA, a fragment of the neuropeptide substance P (SP), induces depressor and bradycardic effects upon application to the nucleus tractus solitarius [1].

HCV-1 e2 Protein (554-569) TFA, an antigenic segment of the hepatitis C virus envelope 2 (e2) protein, contains a potential N-glycosylation site that may influence immune recognition of e2 [1].

MIF-1 TFA (Melanostatin), an intrinsic brain peptide, serves as a powerful allosteric modulator of the dopamine receptor. It plays a crucial role in regulating melanin production and modifies the analgesic efficacy by inhibiting the opioid receptor's effects. Significantly, MIF-1 TFA can cross the blood-brain barrier (BBB) directly, facilitating its access from the bloodstream to the central nervous system (CNS) [1] [2] [3].

GLP-1(9-36)amide TFA, a predominant metabolite of glucagon-like peptide-1-(7-36)amide synthesized through dipeptidyl peptidase-4 (DPP-4) activity, functions as an antagonist to the human pancreatic GLP-1 receptor [1] [2].

187-1, N-WASP Inhibitor TFA, a 14-amino acid cyclic peptide, serves as an allosteric inhibitor of the neural Wiskott-Aldrich syndrome protein (N-WASP). This compound effectively suppresses actin assembly triggered by phosphatidylinositol 4,5-bisphosphate (PIP2), exhibiting a potent inhibitory concentration (IC 50) of 2 μM. Furthermore, 187-1, N-WASP Inhibitor TFA inhibits the activation of the Arp2/3 complex by N-WASP, maintaining the protein in its autoinhibited state, ensuring the prevention of its activation.

GLP-1(28-36)amide TFA, a C-terminal nonapeptide derived from GLP-1 cleavage by neutral endopeptidase (NEP), is an antioxidant that targets mitochondria and inhibits mitochondrial permeability transition (MPT), demonstrating anti-diabetic and cardioprotective effects [1].

Galanin (1-16), mouse, porcine, rat is a potent agonist of the hippocampal galanin receptor with a Kd of 3 nM, and it exhibits high biological activity on locus coeruleus neurons.

ACTH (1-17) TFA is a corticotrophin analogue and an effective human melanocortin 1 (MC1) receptor agonist with Ki value of 0.21 nM.

Angiotensin II is a potent direct vasoconstrictor, causing arteries and veins to constrict, so leading to an increase in blood pressure.

PACAP (1-38), a novel neuropeptide isolated from the bovine hypothalamus is more active than vasoactive intestinal peptide (VIP) in stimulating adenylate cyclase (EC50=7 nM). PACAP 1-38 (10-9 M) increased substance P (SP), gastrin releasing peptide (GRP),

Xenopsin TFA is a neurotensin-like octapeptide derived from the skin of xenopus xenopus.Xenopsin TFA is an inhibitor of tetrachloroside to stimulate gastric acid secretion.

GLP-1 (1-36) amide (human, rat) TFA, a variant of GLP-1 (7-36) amide, induces [14C]aminopyrine accumulation in enzymatically dispersed enriched rat parietal cells [1].

Adrenocorticotropic Hormone (ACTH) (1-39), rat (TFA), is a potent agonist of the melanocortin 2 receptor (MC2).

BA 1 TFA acts as a potent agonist for the bombesin (BB) family of receptors, exhibiting high affinity binding to Bombesin receptor subtype-3 (BRS3), gastrin-releasing peptide receptor (GRPR), and neuromedin B receptor (NMBR), with IC50 values of 6, 0.4, and 2.5 nM, respectively [1].